What Leqvio treats
Leqvio (inclisiran) is a medication used to lower cholesterol levels in individuals with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia. It is designed to reduce low-density lipoprotein cholesterol (LDL-C) levels by targeting and inhibiting a specific protein involved in cholesterol production. Leqvio offers a novel approach to managing high cholesterol, helping to reduce cardiovascular risk and improve overall heart health.
Benefits of Leqvio
Patients using Leqvio often experience significant benefits, including substantial reductions in LDL-C levels and a lower risk of cardiovascular events such as heart attacks and strokes. The extended dosing schedule of Leqvio—initially followed by a dose at three months and then every six months—offers a convenient and effective long-term treatment option for managing high cholesterol.
Possible Side Effects of Leqvio
While Leqvio is generally well-tolerated, some patients may experience side effects, including injection site reactions such as redness or swelling, and mild flu-like symptoms. Serious side effects are rare but can include allergic reactions or liver enzyme abnormalities. It’s important to monitor your health closely and report any unusual symptoms to your healthcare provider.
How infusion works at Prime
Leqvio is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Leqvio, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Leqvio Work?
Leqvio works by targeting and inhibiting the production of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that plays a key role in regulating LDL-C levels. By blocking PCSK9, Leqvio increases the liver’s ability to remove LDL-C from the bloodstream, resulting in lower overall cholesterol levels. Leqvio is administered through subcutaneous injections, with an initial dose followed by a second dose at three months, and then every six months thereafter.
Who is Leqvio For?
Leqvio is suitable for adults with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia who require additional cholesterol-lowering treatment despite being on statin therapy or who cannot tolerate statins. It is particularly recommended for patients who have not achieved target LDL-C levels with other treatments or who need further reduction in cholesterol levels to manage cardiovascular risk.